Lixte Biotechnology to Discuss its Collaboration with Leading European Cancer Centers at the Benzinga Global Small Cap Conference on October 28
20 Ottobre 2021 - 3:25PM
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage
drug discovery company developing pharmacologically active drugs
for use in cancer treatment, will present at the Benzinga Global
Small Cap Conference being held virtually October 27-28, 2021.
Event and Registration: Benzinga Global Small Cap
ConferencePresentation Date: Thursday, October 28,
2021Presentation Time: 11:55 a.m. ET
Lixte Founder and CEO John S. Kovach, M.D. will
deliver a summary of the main features of its lead clinical
compound, the PP2A inhibitor LB-100, and an overview of the
Company’s collaboration with Netherlands Cancer Institute
(Amsterdam) and Oncode Institute (Utrecht) to identify the most
promising drug combinations for LB-100 for cancer treatment. The
pre-clinical studies are directed by Professor René Bernards (NKI),
a leader in using genome wide functional genetic techniques to
identify effective drug combinations, new drug targets, and
mechanisms of resistance to cancer drugs.
Commenting on the collaboration, Dr. Kovach
recently stated, “We are extremely pleased to have the opportunity
to collaborate with Professor Bernards and his excellent group.
There are many pre-clinical studies demonstrating the ability of
our lead compound, LB-100, an inhibitor of protein phosphatase 2A,
to potentiate the activity of different cytotoxic drugs. Its
ubiquitous activity and low toxicity have made it challenging to
select the most promising clinical targets for this novel compound.
A targeted approach to cancer treatment has been a long-standing
research goal. Prof. Bernards’ approach makes it possible to select
among a multitude of compounds those most likely to be effective
when combined with a second drug and/or in cancers with a
particular molecular abnormality. The possibility of identifying
which drug in combination with LB-100 and in which type of tumor is
most likely to be beneficial is a very exciting prospect.”
About Lixte
Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings,
Inc. (Nasdaq:LIXT) is a clinical-stage pharmaceutical company
dedicated to discovering drugs for more effective treatments for
many forms of cancer and other serious common diseases. A major
driver of cancer is defects in the switches that turn the
biochemical pathways in cells on and off. Most cancer research over
the past 30 years has focused on the “on” switches because the
“off” switches, especially the master “off” switch protein
phosphatase (PP2A), were believed to cause intolerable toxicity in
patients. Lixte has achieved a breakthrough with its novel,
first-in-class lead compound, PP2A inhibitor LB-100, by
demonstrating that it is readily tolerated in cancer patients at
doses associated with anti-cancer activity. This innovative
approach encourages cancer cells, damaged by chemo or other cancer
therapies, to continue to replicate before repairing the damage,
leading to the more efficient death and elimination of those cells
from the body. Lixte has partnered with top medical
institutions and leading academic research centers to advance the
clinical development of its compounds. The LB-100 compound, of
which there are no competitors known to Lixte, is being tested in
three clinical cancer treatment studies with others in planning.
lixte.com
Forward-Looking Statements
This announcement contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, and Section 21E of the Securities Exchange
Act of 1934. For example, statements regarding the Company's
financial position, business strategy and other plans and
objectives for future operations, and assumptions and predictions
about future product demand, supply, manufacturing, costs,
marketing and pricing factors are all forward-looking statements.
These statements are generally accompanied by words such as
"intend," anticipate," "believe," "estimate," "potential(ly),"
"continue," "forecast," "predict," "plan," "may," "will," "could,"
"would," "should," "expect" or the negative of such terms or other
comparable terminology. The Company believes that the assumptions
and expectations reflected in such forward-looking statements are
reasonable, based on information available to it on the date
hereof, but the Company cannot provide assurances that these
assumptions and expectations will prove to have been correct or
that the Company will take any action that the Company may
presently be planning. However, these forward-looking statements
are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially
from those expected or anticipated in the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, regulatory policies,
available cash, research results, competition from other similar
businesses, and market and general economic factors. This
discussion should be read in conjunction with the Company's filings
with the United States Securities and Exchange Commission
at sec.gov/edgar.shtml.
Lixte Contact: info@lixte.comGeneral Phone:
(631) 830-7092Investor Phone: (888) 289-5533
Grafico Azioni Lixte Biotechnology (NASDAQ:LIXT)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Lixte Biotechnology (NASDAQ:LIXT)
Storico
Da Lug 2023 a Lug 2024